Cimeio Therapeutics
  • Home
  • About Us
  • Publications
  • News
  • Contact Us
  • Careers
Select Page

Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies

by admin | Dec 9, 2024 | Press Release

Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies — Collaboration leverages Cimeio’s novel epitope shielding and immunotherapy discovery expertise — — Cimeio is eligible to receive an upfront payment and two...

Cimeio Therapeutics Announces Publication in Nature Demonstrating That CD45 ADC and Shielded HSCs Represent a Potentially Universal Therapy for Blood Cancers

by admin | May 22, 2024 | Press Release

Cimeio Therapeutics Announces Publication in Nature Demonstrating That CD45 ADC and Shielded HSCs Represent a Potentially Universal Therapy for Blood Cancers — Selective and complete eradication of leukemic cells with an ADC targeting the pan-blood marker CD45...

Cimeio Therapeutics Presents Data for its CD52 Shielding Variant at ASGCT

by admin | May 9, 2024 | Press Release

Cimeio Therapeutics Presents Data for its CD52 Shielding Variant at ASGCT — Cimeio’s CD52 shielding variant protects cells from depletion by Alemtuzumab while maintaining processing, cell surface expression and function — — Program serves as the...

Hematopoietic Stem Cells Expressing Engineered CD45 Enable a Near Universal Targeted Therapy for Hematologic Diseases

by admin | Dec 16, 2023 | Publication

Hematopoietic Stem Cells Expressing Engineered CD45 Enable a Near Universal Targeted Therapy for Hematologic Diseases Romina Marone1,2*, Simon Garaudé1,2*, Rosalba Lepore1, 2, 3, Anna Devaux1,2, Astrid Beerlage1, 2, Federico Simonetta4,5, Anna Camus3, Izabela...

Cimeio Therapeutics Presents Data for its CD45 Universal Heme ADC at ASH

by admin | Dec 11, 2023 | Press Release

Cimeio Therapeutics Presents Data for its CD45 Universal Heme ADC at ASH — Preclinical data for Cimeio’s CD45 universal heme ADC and shielded HSCs demonstrate effective depletion of an aggressive AML cell line in vivo — — First data for Cimeio’s CD33...
« Older Entries

Recent Posts

  • Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies
  • Cimeio Therapeutics Therapy Platform Featured in Forbes Article
  • Selective haematological cancer eradication with preserved haematopoiesis
  • Cimeio Therapeutics Announces Publication in Nature Demonstrating That CD45 ADC and Shielded HSCs Represent a Potentially Universal Therapy for Blood Cancers
  • Molecular shielding of CD52 retains expression, anti-phagocytic ‘don’t eat me’ function and protects from Alemtuzumab-mediated depletion

Recent Comments

No comments to show.
Cimeio Therapeutics Logo

Transforming Hematopoietic Stem Cell Transplant and Adoptive Cell Therapies


Cimeio Therapeutics, Inc.
1 Broadway, 14th floor
Cambridge, MA 02142
USA


+41 61 225 46 00

Sitemap

  • Home
  • About Us
  • Publications
  • News
  • Contact Us
  • Careers

© 2022-2023 Cimeio Therapeutics, Inc.

  • Follow
Contact Us
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}